Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01335399
Registration number
NCT01335399
Ethics application status
Date submitted
13/04/2011
Date registered
14/04/2011
Date last updated
30/09/2022
Titles & IDs
Public title
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Query!
Scientific title
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Query!
Secondary ID [1]
0
0
2010-022445-20
Query!
Secondary ID [2]
0
0
CA204-006
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ELOQUENT - 1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Other cancer types
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Lenalidomide
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Dexamethasone
Treatment: Other - Elotuzumab (BMS-901608; HuLuc63)
Treatment: Other - Elotuzumab (BMS-901608; HuLuc63)
Active comparator: Lenalidomide + Dexamethasone -
Experimental: Lenalidomide + Dexamethasone + Elotuzumab -
Treatment: Drugs: Lenalidomide
Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
Treatment: Drugs: Dexamethasone
Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
Treatment: Drugs: Dexamethasone
Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Treatment: Drugs: Dexamethasone
Tablets, Oral, 40 mg, once daily, on Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Treatment: Drugs: Dexamethasone
Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Treatment: Other: Elotuzumab (BMS-901608; HuLuc63)
Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Treatment: Other: Elotuzumab (BMS-901608; HuLuc63)
Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS is defined as the time from randomization to the date of the first documented tumor progression (as determined by the Independent Review Committee (IRC)) or death due to any cause.
The IRC conducted a blinded, independent review of the tumor assessments based on the European Group for Blood and Bone Marrow Transplant (EBMT) criteria.
Censoring rules applied:
* Participants receiving subsequent systemic anti-myeloma therapy prior to documented progression were censored at the date of the last adequate tumor assessment prior to new therapy.
* Participants who had an event (progression or death) \> 10 weeks after their last tumor assessment were censored at their last adequate tumor assessment prior to the event.
* Participants without progression or death (and not receiving subsequent therapy prior to progression) were censored at their last adequate tumor assessment.
* Participants without any post-baseline tumor assessments were censored on the date of randomization
Query!
Timepoint [1]
0
0
From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)
Query!
Secondary outcome [1]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [1]
0
0
ORR is defined as the percentage of participants with objective response among all randomized subjects. Participants with an objective response are those participants experiencing a partial response (PR) or better, based on Independent Review Committee (IRC) assessment, as per EBMT criteria.
Query!
Timepoint [1]
0
0
From randomization to primary completion date (approximately 8 years)
Query!
Secondary outcome [2]
0
0
Overall Survival (OS)
Query!
Assessment method [2]
0
0
Survival is defined as the time from randomization to the date of death. A participant who did not die had his or her survival duration censored at the date of last contact ('last known date alive").
Query!
Timepoint [2]
0
0
From randomization to the date of death (up to 8 years)
Query!
Secondary outcome [3]
0
0
Mean Change From Baseline of Pain Severity Score and Pain Interference Score
Query!
Assessment method [3]
0
0
Pain severity (sensory dimension) and pain interference (reactive dimension, assessing the degree to which pain interferes with function) are measured using the Brief Pain Inventory- Short Form (BPI-SF).
BPI-SF numeric rating scale goes from 0 (No pain) to 10 (Pain as bad as you can imagine).
Query!
Timepoint [3]
0
0
From Baseline to End of Treatment (approximately 8 years)
Query!
Secondary outcome [4]
0
0
Progression Free Survival (PFS) Rate at Specific Time-points
Query!
Assessment method [4]
0
0
PFS rate is defined as the percentage of participants experiencing PFS at the defined time-points.
Query!
Timepoint [4]
0
0
From randomization to the specified time-point (up to 5 years)
Query!
Eligibility
Key inclusion criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
* Subjects who are newly diagnosed with symptomatic Multiple Myeloma (MM) and who:
* have not received any prior systemic anti-myeloma therapy AND
* have measurable disease AND
* are not candidates for high-dose therapy plus stem-cell transplantation (SCT) because of age (= 65 years) or coexisting conditions. Refusal to undergo high dose therapy with SCT is NOT sufficient for entry onto CA204006 for a subject < 65 years old. There must be a comorbidity that prevents SCT for a subject < 65 years old
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Subjects with non-secretory or oligo-secretory or free light-chain only myeloma
* Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions
* Monoclonal Gammopathy of Undetermined Significance (MGUS)
* Active plasma cell leukemia
* Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
4/08/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
3/09/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
748
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Local Institution - 3600 - Garran
Query!
Recruitment hospital [2]
0
0
Local Institution - 3607 - Waratah
Query!
Recruitment hospital [3]
0
0
Local Institution - 3610 - Westmead
Query!
Recruitment hospital [4]
0
0
Local Institution - 3609 - Herston
Query!
Recruitment hospital [5]
0
0
Local Institution - 3608 - Milton
Query!
Recruitment hospital [6]
0
0
Local Institution - 3612 - Adelaide
Query!
Recruitment hospital [7]
0
0
Local Institution - 3606 - Woodville South
Query!
Recruitment hospital [8]
0
0
Local Institution - 3601 - Fitzroy
Query!
Recruitment hospital [9]
0
0
Local Institution - 3602 - Frankston
Query!
Recruitment hospital [10]
0
0
Local Institution - 3603 - Heidelberg Melbourne
Query!
Recruitment hospital [11]
0
0
Local Institution - 3604 - Wodonga
Query!
Recruitment hospital [12]
0
0
Local Institution - 3605 - Murdoch
Query!
Recruitment hospital [13]
0
0
Local Institution - 3611 - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2605 - Garran
Query!
Recruitment postcode(s) [2]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [4]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [5]
0
0
4064 - Milton
Query!
Recruitment postcode(s) [6]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [7]
0
0
5001 - Woodville South
Query!
Recruitment postcode(s) [8]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [9]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [10]
0
0
3084 - Heidelberg Melbourne
Query!
Recruitment postcode(s) [11]
0
0
3690 - Wodonga
Query!
Recruitment postcode(s) [12]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [13]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
District of Columbia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Hawaii
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Indiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Iowa
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kentucky
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Louisiana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Maryland
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Massachusetts
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Michigan
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Missouri
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Nebraska
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New York
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
North Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Ohio
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Oklahoma
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Pennsylvania
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
South Carolina
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
South Dakota
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Tennessee
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Texas
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Utah
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Virginia
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Washington
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
West Virginia
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Wisconsin
Query!
Country [33]
0
0
Austria
Query!
State/province [33]
0
0
Fadingerstraße 1
Query!
Country [34]
0
0
Austria
Query!
State/province [34]
0
0
Innsbruck
Query!
Country [35]
0
0
Austria
Query!
State/province [35]
0
0
Rankweil
Query!
Country [36]
0
0
Austria
Query!
State/province [36]
0
0
Wels
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Brussels
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Brussles
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Charleroi
Query!
Country [40]
0
0
Belgium
Query!
State/province [40]
0
0
Haine St Paul
Query!
Country [41]
0
0
Belgium
Query!
State/province [41]
0
0
Leuven
Query!
Country [42]
0
0
Belgium
Query!
State/province [42]
0
0
Liege
Query!
Country [43]
0
0
Belgium
Query!
State/province [43]
0
0
Roeselare
Query!
Country [44]
0
0
Belgium
Query!
State/province [44]
0
0
Yvoir
Query!
Country [45]
0
0
Canada
Query!
State/province [45]
0
0
Alberta
Query!
Country [46]
0
0
Canada
Query!
State/province [46]
0
0
Manitoba
Query!
Country [47]
0
0
Canada
Query!
State/province [47]
0
0
New Brunswick
Query!
Country [48]
0
0
Canada
Query!
State/province [48]
0
0
Nova Scotia
Query!
Country [49]
0
0
Canada
Query!
State/province [49]
0
0
Ontario
Query!
Country [50]
0
0
Canada
Query!
State/province [50]
0
0
Quebec
Query!
Country [51]
0
0
Czechia
Query!
State/province [51]
0
0
Hradec Kralove
Query!
Country [52]
0
0
Czechia
Query!
State/province [52]
0
0
Praha 10
Query!
Country [53]
0
0
Czechia
Query!
State/province [53]
0
0
Praha 2
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Aschaffenburg
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Berlin
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Chemnitz
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Dresden
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Hamm
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Heidelberg
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Jena
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Koln
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Mainz
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Munchen
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Munster
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Offenbach
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Stuttgart
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Tuebingen
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Ulm
Query!
Country [69]
0
0
Greece
Query!
State/province [69]
0
0
Athens
Query!
Country [70]
0
0
Greece
Query!
State/province [70]
0
0
Ioannina
Query!
Country [71]
0
0
Greece
Query!
State/province [71]
0
0
Larissa
Query!
Country [72]
0
0
Greece
Query!
State/province [72]
0
0
Patras
Query!
Country [73]
0
0
Hungary
Query!
State/province [73]
0
0
Budapest
Query!
Country [74]
0
0
Hungary
Query!
State/province [74]
0
0
Debrecen
Query!
Country [75]
0
0
Hungary
Query!
State/province [75]
0
0
Gyor
Query!
Country [76]
0
0
Hungary
Query!
State/province [76]
0
0
Szeged
Query!
Country [77]
0
0
Ireland
Query!
State/province [77]
0
0
Dublin
Query!
Country [78]
0
0
Ireland
Query!
State/province [78]
0
0
Galway
Query!
Country [79]
0
0
Israel
Query!
State/province [79]
0
0
Afula
Query!
Country [80]
0
0
Israel
Query!
State/province [80]
0
0
Ashkelon
Query!
Country [81]
0
0
Israel
Query!
State/province [81]
0
0
Haifa
Query!
Country [82]
0
0
Israel
Query!
State/province [82]
0
0
Jerusalem
Query!
Country [83]
0
0
Israel
Query!
State/province [83]
0
0
Kfar Saba
Query!
Country [84]
0
0
Israel
Query!
State/province [84]
0
0
Nahariya
Query!
Country [85]
0
0
Israel
Query!
State/province [85]
0
0
Petah Tikva
Query!
Country [86]
0
0
Israel
Query!
State/province [86]
0
0
Tel Aviv
Query!
Country [87]
0
0
Israel
Query!
State/province [87]
0
0
Zerifin
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Ancona
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Bari
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Bergamo
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
Bologna
Query!
Country [92]
0
0
Italy
Query!
State/province [92]
0
0
Firenze
Query!
Country [93]
0
0
Italy
Query!
State/province [93]
0
0
Genova
Query!
Country [94]
0
0
Italy
Query!
State/province [94]
0
0
Meldola
Query!
Country [95]
0
0
Italy
Query!
State/province [95]
0
0
Milano
Query!
Country [96]
0
0
Italy
Query!
State/province [96]
0
0
Milan
Query!
Country [97]
0
0
Italy
Query!
State/province [97]
0
0
Monza
Query!
Country [98]
0
0
Italy
Query!
State/province [98]
0
0
Napoli
Query!
Country [99]
0
0
Italy
Query!
State/province [99]
0
0
Palermo
Query!
Country [100]
0
0
Italy
Query!
State/province [100]
0
0
Ravenna
Query!
Country [101]
0
0
Italy
Query!
State/province [101]
0
0
Reggio Nell Emilia (RE)
Query!
Country [102]
0
0
Italy
Query!
State/province [102]
0
0
Rimini
Query!
Country [103]
0
0
Italy
Query!
State/province [103]
0
0
Roma
Query!
Country [104]
0
0
Italy
Query!
State/province [104]
0
0
Rome
Query!
Country [105]
0
0
Italy
Query!
State/province [105]
0
0
Terni
Query!
Country [106]
0
0
Italy
Query!
State/province [106]
0
0
Torino
Query!
Country [107]
0
0
Poland
Query!
State/province [107]
0
0
Bialystok
Query!
Country [108]
0
0
Poland
Query!
State/province [108]
0
0
Chorzow
Query!
Country [109]
0
0
Poland
Query!
State/province [109]
0
0
Gdansk
Query!
Country [110]
0
0
Poland
Query!
State/province [110]
0
0
Krakow
Query!
Country [111]
0
0
Poland
Query!
State/province [111]
0
0
Lodz
Query!
Country [112]
0
0
Poland
Query!
State/province [112]
0
0
Lublin
Query!
Country [113]
0
0
Poland
Query!
State/province [113]
0
0
Poznan
Query!
Country [114]
0
0
Poland
Query!
State/province [114]
0
0
Szczecin
Query!
Country [115]
0
0
Poland
Query!
State/province [115]
0
0
Warszawa
Query!
Country [116]
0
0
Poland
Query!
State/province [116]
0
0
Wroclaw
Query!
Country [117]
0
0
Puerto Rico
Query!
State/province [117]
0
0
Ponce
Query!
Country [118]
0
0
Puerto Rico
Query!
State/province [118]
0
0
San Juan
Query!
Country [119]
0
0
Romania
Query!
State/province [119]
0
0
Brasov
Query!
Country [120]
0
0
Romania
Query!
State/province [120]
0
0
Bucaresti
Query!
Country [121]
0
0
Romania
Query!
State/province [121]
0
0
Bucuresti
Query!
Country [122]
0
0
Romania
Query!
State/province [122]
0
0
Lasi
Query!
Country [123]
0
0
Russian Federation
Query!
State/province [123]
0
0
Samara
Query!
Country [124]
0
0
Russian Federation
Query!
State/province [124]
0
0
St. Petersburg
Query!
Country [125]
0
0
Spain
Query!
State/province [125]
0
0
Badalona-barcelona
Query!
Country [126]
0
0
Spain
Query!
State/province [126]
0
0
Barcelona
Query!
Country [127]
0
0
Spain
Query!
State/province [127]
0
0
La Laguna- Tenerife
Query!
Country [128]
0
0
Spain
Query!
State/province [128]
0
0
Madrid
Query!
Country [129]
0
0
Spain
Query!
State/province [129]
0
0
Pamplona
Query!
Country [130]
0
0
Spain
Query!
State/province [130]
0
0
Salamanca
Query!
Country [131]
0
0
Spain
Query!
State/province [131]
0
0
San Sebastian
Query!
Country [132]
0
0
Spain
Query!
State/province [132]
0
0
Toledo
Query!
Country [133]
0
0
Switzerland
Query!
State/province [133]
0
0
Bern
Query!
Country [134]
0
0
Switzerland
Query!
State/province [134]
0
0
St Gallen
Query!
Country [135]
0
0
Switzerland
Query!
State/province [135]
0
0
Zurich
Query!
Country [136]
0
0
Turkey
Query!
State/province [136]
0
0
Bornova
Query!
Country [137]
0
0
Turkey
Query!
State/province [137]
0
0
Dikimevi
Query!
Country [138]
0
0
Turkey
Query!
State/province [138]
0
0
Inciralti
Query!
Country [139]
0
0
Turkey
Query!
State/province [139]
0
0
Gaziantep
Query!
Country [140]
0
0
United Kingdom
Query!
State/province [140]
0
0
Antrim
Query!
Country [141]
0
0
United Kingdom
Query!
State/province [141]
0
0
Greater London
Query!
Country [142]
0
0
United Kingdom
Query!
State/province [142]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
AbbVie
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS)
Query!
Trial website
https://clinicaltrials.gov/study/NCT01335399
Query!
Trial related presentations / publications
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksac M, Legiec W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Spicka I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/99/NCT01335399/Prot_001.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/99/NCT01335399/SAP_000.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT01335399
Download to PDF